Bioequivalence Methods For Modified-Release Drugs To Be Examined By USP
This article was originally published in The Tan Sheet
The U.S. Pharmacopeia plans to take a role in developing bioequivalence methods for modified- and immediate-release drugs.
You may also be interested in...
A resolution concerning the reduction of medical errors through labeling and packaging standards would apply to OTC drugs, the U.S. Pharmacopeia's Resolutions Committee decided at USP's quinquennial meeting in Washington, D.C. April 12-16.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning